GBS GLOBAL BIOPHARMA INC has a total of 25 patent applications. It increased the IP activity by 166.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals and measurement are KLARIA PHARMA HOLDING AB, AIVIVA BIOPHARMA INC and Guizhou shenqi pharmaceutical co ltd.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | Australia | 4 | |
#3 | Canada | 4 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | Israel | 4 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Small-Howard Andrea | 21 |
#2 | Turner Helen | 20 |
#3 | El-Hammadi Mazen | 1 |
#4 | Arévalo Mercedes Fernández | 1 |
#5 | Banderas Lucia Martin | 1 |
Publication | Filing date | Title |
---|---|---|
US2020405657A1 | Treatment of pain using allosteric modulator of trpv1 | |
US2020155469A1 | Therapeutic nanoparticles encapsulating terpenoids and/or cannabinoids | |
WO2019226833A1 | Cannabinoids and/or terpenes for use in trpv1 modulation | |
CN110913839A | Myrcene and cannabinoid containing compositions targeted to TRPV1 | |
AU2018215200A1 | Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders | |
AU2017344040A1 | Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases |